First‐line treatment of multiple myeloma, a prevalent blood cancer lacking a cure, using anti‐CD38 daratumumab antibody and lenalidomide is often inadequate due to relapse and severe side effects. The gene discussed is CD38; the disease is hematopoietic and lymphoid system neoplasm.